Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Consensus Target Price of $129.83

Key Points

• Analysts remain broadly bullish on Dianthus Therapeutics, with 13 buy, one strong-buy, and one sell rating producing a “Moderate Buy” consensus. The average 12-month price target is $129.83, above the reported $84.88 share price.
• Insiders sold heavily: company insiders sold 242,429 shares worth approximately $26.1 million over the past three months, reducing insider ownership to 3.02%. Institutional investors own 47.53% of the stock.
• Dianthus reported a quarterly loss of $0.90 per share, missing the $0.85 consensus estimate, while revenue of $0.76 million exceeded expectations. Analysts expect a full-year loss of $3.81 per share.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fifteen analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $129.83.

A number of research analysts have recently commented on DNTH shares. Guggenheim reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They issued an "overweight" rating and a $135.00 target price for the company. Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Finally, TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th.

Insider Activity at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This represents a 85.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anne McGeorge sold 7,750 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director owned 1,250 shares in the company, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 242,429 shares of company stock worth $26,118,913 in the last three months. 3.02% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Arizona State Retirement System grew its position in shares of Dianthus Therapeutics by 5.7% in the second quarter. Arizona State Retirement System now owns 10,141 shares of the company's stock valued at $989,000 after purchasing an additional 546 shares during the last quarter. Nykredit A S bought a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $147,000. Amundi acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $287,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $1,033,000. Finally, Alyeska Investment Group L.P. lifted its holdings in Dianthus Therapeutics by 188.2% during the 2nd quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company's stock worth $14,680,000 after purchasing an additional 98,345 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Down 0.6%

Shares of Dianthus Therapeutics stock opened at $84.88 on Thursday. The stock has a market cap of $4.65 billion, a P/E ratio of -20.45 and a beta of 1.35. Dianthus Therapeutics has a 12-month low of $32.22 and a 12-month high of $117.88. The business's 50 day moving average is $103.75 and its 200-day moving average is $94.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. On average, sell-side analysts expect that Dianthus Therapeutics will post -3.81 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company's approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus' lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.